BRPI0408417A - métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição - Google Patents

métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição

Info

Publication number
BRPI0408417A
BRPI0408417A BRPI0408417-9A BRPI0408417A BRPI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A BR PI0408417 A BRPI0408417 A BR PI0408417A
Authority
BR
Brazil
Prior art keywords
serine protease
gla residue
containing gla
purifying
residue
Prior art date
Application number
BRPI0408417-9A
Other languages
English (en)
Inventor
Janus Krarup
Egon Persson
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Publication of BRPI0408417A publication Critical patent/BRPI0408417A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MéTODOS PARA A PRODUçãO DE UM RESìDUO DE GLA PURIFICADO CONTENDO SERINA PROTEASE, PARA A PURIFICAçãO DE UM RESìDUO DE GLA CONTENDO SERINA PROTEASE E PARA ESTABILIZAçãO DE UM RESìDUO DE GLA CONTENDO SERINA PROTEASE, E, COMPOSIçãO". A presente invenção diz respeito a um processo para a purificação de uma protease.
BRPI0408417-9A 2003-03-18 2004-03-18 métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição BRPI0408417A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300413 2003-03-18
US45780903P 2003-03-26 2003-03-26
PCT/DK2004/000183 WO2004083421A1 (en) 2003-03-18 2004-03-18 Method for the production of gla-residue containing serine proteases

Publications (1)

Publication Number Publication Date
BRPI0408417A true BRPI0408417A (pt) 2006-03-21

Family

ID=33031170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408417-9A BRPI0408417A (pt) 2003-03-18 2004-03-18 métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição

Country Status (10)

Country Link
EP (2) EP3103869A1 (pt)
JP (1) JP4885707B2 (pt)
KR (1) KR101204712B1 (pt)
CN (4) CN101818138A (pt)
AU (1) AU2004221758B2 (pt)
BR (1) BRPI0408417A (pt)
CA (1) CA2519020A1 (pt)
MX (1) MXPA05009770A (pt)
RU (1) RU2364626C2 (pt)
WO (1) WO2004083421A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
US7985569B2 (en) * 2003-11-19 2011-07-26 Danisco Us Inc. Cellulomonas 69B4 serine protease variants
CN101184474B (zh) * 2005-04-28 2013-05-29 诺和诺德医疗保健公司 含有活化的凝血因子ⅶ多肽的密封容器，制备这种容器的方法，和试剂盒以及该试剂盒的使用方法
AU2012213951B2 (en) * 2005-04-28 2014-10-16 Novo Nordisk Health Care Ag A closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit
BRPI0615247A2 (pt) * 2005-08-31 2011-05-10 Novo Nordisk Healthcare Ag anticorpos especÍficos para fvii e uso desses
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010063717A1 (en) * 2008-12-02 2010-06-10 Novo Nordisk A/S Polypeptide purification
JP6250931B2 (ja) 2010-01-18 2017-12-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 血液凝固因子の精製
MX356527B (es) * 2010-07-09 2018-06-01 Bioverativ Therapeutics Inc Polipeptidos de factor ix y metodos para usarlos.
WO2012173260A1 (ja) 2011-06-17 2012-12-20 学校法人東日本学園・北海道医療大学 ループスアンチコアグラント検出用血液凝固時間の測定方法
CN103539852B (zh) * 2012-07-12 2015-08-12 上海泰龙生物医药科技有限公司 一种从细胞培养液中分离纯化重组人凝血八因子的方法
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN109876136B (zh) * 2019-02-21 2019-12-31 国药集团成都信立邦生物制药有限公司 一种醋酸奥曲肽冻干粉针剂及其制备方法
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8615942D0 (en) 1986-06-30 1986-08-06 Animal & Food Research Council Peptide production
NZ221259A (en) 1986-07-31 1990-05-28 Calgene Inc Seed specific transcriptional regulation
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8826446D0 (en) 1988-11-11 1988-12-14 Agricultural & Food Res Peptide production
JP2824430B2 (ja) * 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
US5073964A (en) 1989-08-04 1991-12-17 Aware, Inc. Signal processing device and method
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP0521873B1 (en) 1990-01-29 1999-06-02 Zymogenetics, Inc. Anticoagulant proteins
JPH06507307A (ja) 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
FR2684999A1 (fr) 1991-12-16 1993-06-18 Aquitaine Dev Transf Sanguine Procede de fabrication d'un concentre de facteur vii active de haute purete essentiellement depourvu des facteurs vitamine k dependants et des facteurs viiic et viiicag.
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
DE19538715A1 (de) 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US5925738A (en) * 1995-12-01 1999-07-20 The American National Red Cross Methods of production and use of liquid formulations of plasma proteins
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE19937219A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Ionenaustauscherchromatographie
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ATE264340T1 (de) * 1999-08-17 2004-04-15 Novo Nordisk Healthcare Ag Stabilisierung von gefriergetrocknetem kuchen
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
DE60138364D1 (de) * 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
IL154520A0 (en) 2000-09-13 2003-09-17 Novo Nordisk As Human coagulation factor vii variants
BR0114374A (pt) * 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
PL371800A1 (en) 2001-03-22 2005-06-27 Novo Nordisk Health Care Ag Coagulation factor vii derivatives
AU2003223925A1 (en) * 2002-05-03 2003-11-17 Novo Nordisk A/S Stabilised solid compositions of modified factor vii

Also Published As

Publication number Publication date
JP2006520200A (ja) 2006-09-07
EP1611236A1 (en) 2006-01-04
MXPA05009770A (es) 2005-11-17
RU2005132170A (ru) 2007-06-20
CA2519020A1 (en) 2004-09-30
CN101818138A (zh) 2010-09-01
RU2364626C2 (ru) 2009-08-20
CN101818137A (zh) 2010-09-01
EP3103869A1 (en) 2016-12-14
CN1761747A (zh) 2006-04-19
KR101204712B1 (ko) 2012-11-27
JP4885707B2 (ja) 2012-02-29
CN1780637A (zh) 2006-05-31
KR20050110016A (ko) 2005-11-22
AU2004221758A1 (en) 2004-09-30
WO2004083421A1 (en) 2004-09-30
AU2004221758B2 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
BRPI0408417A (pt) métodos para a produção de um resìduo de gla purificado contendo serina protease, para a purificação de um resìduo de gla contendo serina protease e para estabilização de um resìduo de gla contendo serina protease, e, composição
PL367527A1 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
UA95083C2 (ru) Азеотропная или близкая к азеотропной композиции, которые содержат 1,1,1,2,3-пентафторопропен и фтороводород, способы отделения и получения 1,1,1,2,3-пентафторопропена
ATE452870T1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
DE60201480D1 (de) Verfahren zur Herstellung von hochreinem Xylylendiamin
ATE469189T1 (de) Schwach gefärbte natriumarme benzoxazinon-uv- absorber und verfahren zu ihrer herstellung
BRPI0508973A (pt) método para a purificação de um metal fundido
MXPA05012362A (es) Yodopirazolilcarboxanilidas.
GB0216001D0 (en) Process and composition
DE60205083D1 (de) Verfahren zur herstellung von octafluoropropan
DE60207031D1 (de) Verfahren zur herstellung von octafluorocyclobutan
TW200508179A (en) Purification of dimethylacetamide (DMAc)
DE60114048D1 (de) Verfahren zur aufreinigung von maltose
HUP0301862A2 (hu) Laktámvegyület, a vegyületet tartalmazó gyógyászati készítmény, eljárás elżállítására, köztitermékek és alkalmazása gyógyászati készítmény elżállítására
AU2003258335A1 (en) A method for the purification of lansoprazole
HUP0302530A2 (hu) Eljárás 2-nitro-4-metilszulfonil-benzoesav tisztítására
DE60138712D1 (de) O-butanen
BR0212390A (pt) Processo para a preparação de cilastatina
IT1319679B1 (it) Processo di purificazione di fosfatidilserina.
BRPI0411634A (pt) método e dispositivo para purificação de ar e água
ECSP024388A (es) Inhibidores de proteasas
DE60200535D1 (de) Verfahren zur Herstellung von hoch reinem Pemirolast
BRPI0411652A (pt) processo para a preparação de derivados de espirobenzoazepina substituìdos não-peptìdicos
RS20050778A (sr) Nova jedinjenja fosfonskih kiselina kao inhibitori serin proteaza
MXPA03001272A (es) Procedimiento para la preparacion de dinapsolina.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: NOVO NORDISK HEALTH CARE AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]